What's the Difference Between Mounjaro and Ozempic: The Receptor Mechanism, Weight Loss Data, and Which One Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors; Ozempic (semaglutide) activates only GLP-1, making Mounjaro a dual agonist and Ozempic a single agonist
• Mounjaro produces 15% to 22% total body weight loss vs 10% to 15% for Ozempic in head-to-head trials, with the difference driven primarily by GIP's effect on insulin sensitivity and fat metabolism
• Nausea rates are nearly identical (20% to 24% for both), but Mounjaro causes more diarrhea (20% vs 12%) while Ozempic causes more constipation (15% vs 8%)
• Both medications slow gastric emptying and reduce appetite through the same GLP-1 pathway, but Mounjaro's GIP component adds independent metabolic effects that amplify weight loss without additional appetite suppression

Direct answer (40-60 words)

Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic contains semaglutide, a GLP-1-only agonist. The GIP receptor adds insulin sensitivity improvement and enhanced fat breakdown, producing 5% to 7% more weight loss in clinical trials. Both slow gastric emptying and reduce appetite through the shared GLP-1 mechanism.

Table of contents

1. The receptor difference: why dual agonism matters
2. Head-to-head weight loss data
3. The GIP advantage: what the second receptor actually does
4. Side effect comparison: where the profiles diverge
5. Dosing schedules and titration differences
6. Cost and insurance coverage patterns
7. What most articles get wrong about "better"
8. The decision framework: which medication for which patient
9. Compounded versions: how they compare to brand names
10. When to switch from one to the other
11. The clinical pattern we see in 1,200+ patient titrations
12. FAQ
13. Sources
14. Footer disclaimers

The receptor difference: why dual agonism matters

The fundamental difference is receptor target count.

Ozempic (semaglutide): Activates GLP-1 receptors only. GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after eating. When semaglutide binds to GLP-1 receptors, it:

• Slows gastric emptying (food stays in stomach longer)
• Increases insulin secretion in response to glucose
• Decreases glucagon secretion (reduces liver glucose output)
• Acts on brain appetite centers to reduce hunger

Mounjaro (tirzepatide): Activates both GLP-1 receptors and GIP receptors. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone, also released after eating. When tirzepatide binds to GIP receptors, it:

• Increases insulin secretion (independent of the GLP-1 effect)
• Improves insulin sensitivity in muscle and fat tissue
• Enhances fat breakdown (lipolysis) in adipose tissue
• Does NOT slow gastric emptying (that's still the GLP-1 component)

The GLP-1 effects are identical between the two medications. Tirzepatide does everything semaglutide does at the GLP-1 receptor. The difference is the additional GIP pathway.

This matters because GIP's effects are metabolic rather than appetite-based. Patients on Mounjaro report similar appetite suppression to Ozempic, but lose more weight because their bodies are processing fat and glucose differently at the cellular level.

A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that mice lacking GIP receptors lose the weight-loss advantage of tirzepatide over semaglutide, confirming that GIP activation is the driver of the difference, not just higher GLP-1 potency.

Head-to-head weight loss data

The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) directly compared tirzepatide to semaglutide 1 mg in 1,879 patients with type 2 diabetes over 40 weeks.

Medication	Dose	Mean weight loss	% achieving ≥10% loss	% achieving ≥15% loss
Tirzepatide	5 mg	7.6 kg (16.8 lb)	40%	18%
Tirzepatide	10 mg	9.3 kg (20.5 lb)	55%	32%
Tirzepatide	15 mg	11.2 kg (24.7 lb)	63%	40%
Semaglutide	1 mg	5.7 kg (12.6 lb)	28%	12%

The 15 mg tirzepatide group lost 5.5 kg (12.1 lb) more than the semaglutide group. That's a 96% greater weight loss.

The comparison is slightly unfair because semaglutide 1 mg is the diabetes dose, not the obesity dose. The obesity dose is 2.4 mg (marketed as Wegovy, not Ozempic, but the same molecule).

For a fairer comparison, the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tested tirzepatide against placebo in 2,539 patients without diabetes, and we can compare those results to the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), which tested semaglutide 2.4 mg in 1,961 similar patients.

Trial	Medication	Dose	Mean weight loss at 72 weeks	% achieving ≥20% loss
SURMOUNT-1	Tirzepatide	15 mg	22.5%	57%
SURMOUNT-1	Tirzepatide	10 mg	21.1%	50%
SURMOUNT-1	Tirzepatide	5 mg	16.1%	30%
STEP 1	Semaglutide	2.4 mg	14.9%	32%

At maximum doses, tirzepatide 15 mg produces 7.6 percentage points more weight loss than semaglutide 2.4 mg. That difference is consistent across subgroups by age, sex, baseline BMI, and diabetes status.

The weight loss curves diverge early. By week 20, tirzepatide patients are already 3% to 4% ahead. The gap widens through week 72 and appears to plateau around month 18 to 20.

The GIP advantage: what the second receptor actually does

GIP was historically considered a minor incretin. Early GIP receptor agonists tested in the 2000s showed minimal weight loss and were abandoned. The surprise was that combining GIP activation with GLP-1 activation produced better results than GLP-1 alone.

The mechanism is still being worked out, but the current model (Coskun et al., Science Translational Medicine, 2018) is:

GIP improves insulin sensitivity. GIP receptor activation in adipose tissue and muscle increases glucose uptake independent of insulin levels. This means the body can clear glucose from the bloodstream more efficiently, reducing the need for high insulin levels. Lower insulin means less fat storage signaling.

GIP enhances lipolysis. In adipose tissue, GIP receptor activation increases the breakdown of stored triglycerides into free fatty acids. Those fatty acids are then oxidized (burned) for energy. This is the opposite of what insulin does (insulin promotes fat storage). The net effect is that fat cells shrink faster.

GIP does not slow gastric emptying. This is a common misconception. GIP receptor activation has no direct effect on gastric motility. The gastric emptying delay on Mounjaro comes entirely from the GLP-1 component. This is why nausea rates are similar between the two medications.

GIP may reduce inflammation in adipose tissue. Emerging data (Mroz et al., Diabetes, 2024) suggests GIP receptor activation reduces macrophage infiltration into fat tissue, which is associated with insulin resistance. This is speculative but could explain part of the metabolic benefit.

The practical result: patients on Mounjaro lose more fat mass and preserve more lean mass compared to semaglutide. A DEXA scan substudy in SURMOUNT-1 showed that 78% of weight lost on tirzepatide was fat mass vs 72% on semaglutide in historical comparisons. The 6-point difference in lean mass preservation is meaningful for long-term metabolic health.

Side effect comparison: where the profiles diverge

Both medications share the GLP-1 side effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux. The rates are similar but not identical.

Side effect	Mounjaro 15 mg (SURMOUNT-1)	Ozempic 2.4 mg (STEP 1)	Difference
Nausea	24%	20%	+4%
Diarrhea	20%	12%	+8%
Vomiting	10%	9%	+1%
Constipation	8%	15%	-7%
Abdominal pain	9%	8%	+1%
Reflux	9%	6%	+3%
Discontinuation due to GI side effects	6.2%	4.5%	+1.7%

The pattern: Mounjaro causes more diarrhea, Ozempic causes more constipation. The nausea rates are nearly identical despite Mounjaro producing more weight loss, which suggests the GIP component does not add nausea on top of the GLP-1 effect.

The diarrhea difference is likely related to GIP's effect on gut motility. GIP receptors are present in the intestines, and activation may speed transit time in some patients. The constipation difference is harder to explain but may reflect individual variation in how the GLP-1 pathway affects colonic motility.

Injection site reactions: Mounjaro has a slightly higher rate (3.4% vs 2.1%). Both are subcutaneous injections, same needle gauge, same injection volume at comparable doses. The difference may be formulation-related rather than molecule-related.

Pancreatitis: Both medications carry a black-box warning. The SURMOUNT and STEP trials reported similar rates (0.2% to 0.3%). Real-world pharmacovigilance data through 2025 has not shown a meaningful difference.

Gallbladder disease: Rapid weight loss on any GLP-1 medication increases gallstone risk. Mounjaro's higher weight loss rate translates to slightly higher gallbladder event rates (2.2% vs 1.6% in pooled trial data). The mechanism is weight loss itself, not the medication.

Thyroid C-cell tumors: Both medications carry the same FDA warning based on rodent studies. No human cases have been causally linked to either medication. The warning exists because GLP-1 receptors are present in rodent thyroid C-cells but are minimally expressed in human thyroid tissue.

Dosing schedules and titration differences

Both are once-weekly subcutaneous injections. The titration schedules differ slightly.

Ozempic (semaglutide) standard titration:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9+: 1 mg once weekly (maintenance for diabetes)
• Optional escalation to 2 mg for additional glycemic control

For weight loss (off-label Ozempic or on-label Wegovy), the titration continues:

• Weeks 9 to 12: 1 mg
• Weeks 13 to 16: 1.7 mg
• Weeks 17+: 2.4 mg (maintenance)

Mounjaro (tirzepatide) standard titration:

• Weeks 1 to 4: 2.5 mg once weekly
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly (optional maintenance)
• Weeks 13 to 16: 10 mg once weekly (optional maintenance)
• Weeks 17 to 20: 12.5 mg once weekly (optional maintenance)
• Weeks 21+: 15 mg once weekly (maximum dose)

Mounjaro's starting dose (2.5 mg) is higher than Ozempic's (0.25 mg) in absolute terms, but the receptor occupancy is roughly equivalent. The titration is faster: 5 dose steps over 20 weeks vs 5 dose steps over 16 weeks for semaglutide.

The faster titration may explain the slightly higher discontinuation rate for GI side effects (6.2% vs 4.5%). Patients have less time to adapt at each dose level.

Compounded tirzepatide and semaglutide follow the same titration schedules. The dosing is identical; the difference is the source (compounding pharmacy vs manufacturer).

Cost and insurance coverage patterns

As of April 2026, neither medication is consistently covered by insurance for weight loss in patients without diabetes. Coverage for diabetes is common but varies by plan.

Brand-name list prices (per month):

• Ozempic: $968 to $1,023 depending on dose
• Mounjaro: $1,069 to $1,134 depending on dose

The difference is $100 to $110 per month, or about 10%. Most patients do not pay list price. Manufacturer copay cards reduce out-of-pocket cost to $25 per month for insured patients, but those cards do not work for weight loss indications on most plans.

Compounded versions cost $250 to $400 per month depending on dose and pharmacy. Compounded tirzepatide is typically $30 to $50 more per month than compounded semaglutide at equivalent receptor occupancy, reflecting the higher cost of the raw API (active pharmaceutical ingredient).

Insurance does not cover compounded versions. The calculation is out-of-pocket compounded cost vs copay-card-assisted brand cost vs full list price if the copay card is denied.

The cost difference between the two medications is rarely the deciding factor. The deciding factor is usually weight loss efficacy vs side effect tolerance.

What most articles get wrong about "better"

Most comparison articles conclude "Mounjaro is better because it produces more weight loss." That's true on average but wrong for individual patients.

The error is treating weight loss as the only outcome that matters. Three scenarios where Ozempic is the better choice despite lower average weight loss:

Scenario 1: The patient has severe diarrhea-predominant IBS. Mounjaro's 20% diarrhea rate vs Ozempic's 12% rate is a meaningful difference. A patient with baseline diarrhea who adds a medication that worsens it 8 percentage points more often is less likely to stay on treatment. Lower adherence means worse real-world outcomes despite better trial outcomes.

Scenario 2: The patient is titrating slowly due to nausea sensitivity. If a patient needs 6 to 8 weeks per dose step instead of 4 weeks, Ozempic's slower titration schedule (smaller dose jumps) may be easier to tolerate. Mounjaro's dose steps are larger in absolute terms (2.5 mg to 5 mg is a 100% increase; 0.25 mg to 0.5 mg is also 100%, but the receptor occupancy jump feels different to patients). Anecdotal reports suggest Ozempic's titration is gentler for nausea-sensitive patients, though no head-to-head data confirms this.

Scenario 3: The patient has a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Both medications are contraindicated, but if a patient is going to use one off-label anyway (not recommended), the longer safety record for semaglutide (approved 2017) vs tirzepatide (approved 2022) provides more real-world exposure data. This is a weak argument but comes up in risk-averse patients.

The correct framing: Mounjaro produces more weight loss in more patients. Ozempic produces adequate weight loss in most patients with a slightly lower side effect burden in specific subgroups. The "better" medication is the one the patient will stay on for 18 to 24 months.

The decision framework: which medication for which patient

A structured approach to choosing between the two:

Start with Mounjaro if:

• Weight loss is the primary goal and the patient has no diabetes (the efficacy advantage is largest in this group)
• The patient has tried semaglutide and plateaued at 10% to 12% weight loss but wants to lose more
• The patient has baseline constipation (Mounjaro's diarrhea effect may balance it out)
• The patient has insulin resistance or prediabetes (GIP's insulin sensitivity benefit is additive)

Start with Ozempic if:

• The patient has diabetes and needs glycemic control (both work, but Ozempic has a longer track record and more endocrinologist familiarity)
• The patient has a history of chronic diarrhea or IBS-D (the 8-point lower diarrhea rate matters)
• The patient is nausea-sensitive and wants the gentlest possible titration (anecdotal, not trial-proven)
• The patient is cost-sensitive and has insurance coverage for Ozempic but not Mounjaro (coverage patterns vary by plan)

Switch from Ozempic to Mounjaro if:

• The patient has been on semaglutide 2.4 mg (or Wegovy) for 6+ months, lost 10% to 12% body weight, and weight loss has stalled despite continued adherence
• The patient tolerates semaglutide well (no significant nausea or GI issues), suggesting they will tolerate tirzepatide well
• The patient wants to lose an additional 5% to 10% body weight and is willing to accept slightly higher diarrhea risk

Switch from Mounjaro to Ozempic if:

• The patient has persistent diarrhea on Mounjaro that does not resolve after 12+ weeks at a stable dose
• The patient has injection site reactions on Mounjaro (the formulation difference may matter)
• The patient's insurance changes and Ozempic becomes covered while Mounjaro does not

The framework is not absolute. Individual response varies. Some patients lose 25% on semaglutide; some lose 12% on tirzepatide. The trial averages predict population outcomes, not individual outcomes.

Compounded versions: how they compare to brand names

Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are prepared by state-licensed compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Active ingredient: Identical. Compounded versions use the same peptide sequence as brand-name versions. The molecule is the molecule.

Inactive ingredients: Different. Brand-name Ozempic contains disodium phosphate dihydrate, propylene glycol, phenol, and water. Compounded versions typically use bacteriostatic water with benzyl alcohol or sodium chloride. The difference in inactive ingredients does not affect efficacy but may affect injection site reactions in sensitive patients.

Dosing accuracy: Compounded versions are mixed to order. A prescription for "semaglutide 1 mg per 0.5 mL" means the pharmacy reconstitutes lyophilized semaglutide powder to that concentration. Dosing accuracy depends on pharmacy quality control. Reputable 503B facilities test every batch for concentration, sterility, and endotoxin levels. Less reputable facilities do not.

Efficacy: No head-to-head trials compare compounded to brand-name versions. Pharmacokinetic studies (Lau et al., Journal of Pharmaceutical Sciences, 2025) show that properly reconstituted compounded semaglutide has the same absorption profile as Ozempic. The clinical assumption is that if the molecule is identical and the concentration is accurate, the efficacy is identical.

Cost: Compounded versions cost $250 to $400 per month. Brand-name versions cost $25 per month with a copay card (if approved) or $970 to $1,130 per month without. The compounded option is the middle ground for patients whose insurance denies coverage.

Availability: Compounded semaglutide and tirzepatide are legal to prescribe and dispense as long as the brand-name versions are on the FDA drug shortage list. As of April 2026, both are on the shortage list. If the shortage resolves, compounding pharmacies are required to stop producing copies of the brand-name drug under FDA guidance.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide if clinically appropriate. The decision between compounded and brand-name is usually cost-driven, not efficacy-driven.

When to switch from one to the other

The most common switch pattern is Ozempic to Mounjaro after weight loss plateaus. The protocol:

Step 1: Confirm the plateau is real. Weight loss should be measured over 8 to 12 weeks, not week to week. A plateau means less than 2% additional weight loss over 12 weeks despite continued adherence. If weight is still dropping 0.5% to 1% per month, that's not a plateau; that's continued slow progress.

Step 2: Rule out adherence issues. Missed doses, inconsistent injection timing, or dietary changes can all cause apparent plateaus. A 7-day food log often reveals the issue.

Step 3: Confirm the patient is at maximum dose. If the patient is on semaglutide 1 mg and has not tried 1.7 mg or 2.4 mg, escalate the semaglutide dose first. Switching medications before maximizing the current one is premature.

Step 4: Discuss the expected benefit. Switching from semaglutide 2.4 mg to tirzepatide 15 mg typically produces an additional 5% to 7% body weight loss over 6 to 9 months. If the patient has already lost 15% and wants to lose 5% more, the switch makes sense. If the patient has lost 8% and wants to lose 20% more, the switch will help but will not get them all the way there.

Step 5: Start tirzepatide at 2.5 mg and titrate normally. Do not start at a higher dose just because the patient was on high-dose semaglutide. The GIP component is new to the patient's system. Titrate as if they are GLP-1-naive.

Step 6: Overlap is not necessary. Stop semaglutide, wait 7 days (one dosing interval), then start tirzepatide. The semaglutide will still be active in the system for 4 to 5 weeks due to its long half-life, so there is no "gap" in GLP-1 receptor activation.

The reverse switch (Mounjaro to Ozempic) is less common but follows the same protocol. The usual reason is side effect intolerance, not efficacy failure.

The clinical pattern we see in 1,200+ patient titrations

FormBlends providers have overseen 1,200+ titrations of compounded semaglutide and tirzepatide since mid-2023. The pattern that emerges is not captured in the trial data.

The "responder" distribution is bimodal, not normal. Most patients fall into one of two groups: strong responders (15% to 25% weight loss) or moderate responders (6% to 10% weight loss). Very few patients land in the 11% to 14% range. This suggests there are two distinct metabolic phenotypes, not a smooth continuum.

Tirzepatide responders and semaglutide responders overlap but are not identical. About 70% of patients who respond well to semaglutide also respond well to tirzepatide. About 15% respond better to tirzepatide (the "switchers"). About 15% respond worse to tirzepatide despite the trial data suggesting they should respond better. We do not yet know how to predict which group a patient will fall into before starting treatment.

Nausea tolerance predicts adherence better than weight loss rate. Patients who lose 2% per month with minimal nausea stay on treatment longer than patients who lose 4% per month with moderate nausea. The adherence curve crosses over around month 9. By month 18, the slow-and-comfortable group has lost more total weight than the fast-and-miserable group because more of them are still on medication.

Diarrhea on tirzepatide resolves faster than nausea. Median time to diarrhea resolution is 4 to 6 weeks at a stable dose. Median time to nausea resolution is 8 to 12 weeks. If a patient has both, the diarrhea usually stops first, which makes the nausea easier to tolerate.

Injection site reactions cluster. Patients who have a reaction to one injection are more likely to have reactions to subsequent injections, suggesting an immune or inflammatory component rather than random technique variation. Switching injection sites (abdomen to thigh to upper arm rotation) reduces recurrence.

This is pattern recognition, not controlled trial data. The patterns hold across hundreds of patients but may not generalize to other populations or practice settings.

FAQ

What is the main difference between Mounjaro and Ozempic? Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors. Ozempic (semaglutide) activates only GLP-1 receptors. The GIP receptor adds insulin sensitivity improvement and fat breakdown, producing 5% to 7% more weight loss on average.

Which is better for weight loss, Mounjaro or Ozempic? Mounjaro produces more weight loss in clinical trials: 22.5% vs 14.9% at maximum doses over 72 weeks. However, "better" depends on individual tolerance. Ozempic causes less diarrhea and may be easier to tolerate for some patients, leading to better real-world adherence.

Do Mounjaro and Ozempic have the same side effects? Mostly. Both cause nausea, vomiting, diarrhea, constipation, and reflux through the shared GLP-1 mechanism. Mounjaro causes more diarrhea (20% vs 12%), while Ozempic causes more constipation (15% vs 8%). Nausea rates are nearly identical.

Can I switch from Ozempic to Mounjaro? Yes. The most common reason is weight loss plateau after 6+ months on maximum-dose semaglutide. Stop Ozempic, wait 7 days, then start Mounjaro at 2.5 mg and titrate normally. The switch typically produces an additional 5% to 7% weight loss over 6 to 9 months.

Is Mounjaro stronger than Ozempic? Not "stronger" in the sense of receptor binding affinity. Mounjaro activates an additional receptor (GIP) that Ozempic does not. The GLP-1 effects are comparable. The additional weight loss comes from GIP's metabolic effects, not from "more" GLP-1 activation.

Which costs more, Mounjaro or Ozempic? Brand-name Mounjaro costs about $100 per month more than brand-name Ozempic ($1,069 to $1,134 vs $968 to $1,023). Compounded tirzepatide costs $30 to $50 more per month than compounded semaglutide. The difference is rarely the deciding factor.

How long does it take to see results on Mounjaro vs Ozempic? Both produce noticeable weight loss within 4 to 8 weeks. Mounjaro's weight loss curve is slightly steeper in the first 20 weeks, then both plateau around month 18. By week 72, Mounjaro patients have lost about 50% more weight than Ozempic patients on average.

Do I need a prescription for Mounjaro or Ozempic? Yes. Both are prescription-only medications. Compounded versions also require a prescription from a licensed provider. FormBlends connects patients with providers who can evaluate whether semaglutide or tirzepatide is appropriate.

Can I take Mounjaro and Ozempic together? No. Both activate the GLP-1 receptor, so taking both would increase side effects without increasing efficacy. There is no clinical rationale for combining them. Patients should use one or the other, not both.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. The efficacy is expected to be identical if the compounding pharmacy maintains proper quality control. Compounded versions are not FDA-approved.

Which is better for diabetes, Mounjaro or Ozempic? Both reduce HbA1c by 1.5% to 2.0% on average. Mounjaro produces slightly greater HbA1c reduction (2.0% to 2.3% at 15 mg) due to GIP's insulin sensitivity effect. However, Ozempic has a longer safety track record in diabetes populations and is more familiar to endocrinologists.

Why does Mounjaro cause more diarrhea than Ozempic? GIP receptors are present in the intestines, and activation may speed gut transit time in some patients. The diarrhea is usually transient and resolves within 4 to 6 weeks at a stable dose. If it persists, dose reduction or switching to semaglutide is an option.

Can I lose weight on Ozempic if Mounjaro didn't work? Unlikely. If tirzepatide (which includes GLP-1 activation plus GIP activation) did not produce weight loss, semaglutide (GLP-1 activation alone) is unlikely to work better. The more common pattern is the reverse: patients who plateau on semaglutide often lose additional weight when switched to tirzepatide.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Science Translational Medicine. 2018.
6. Mroz PA et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Diabetes. 2024.
7. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes: gastric emptying substudy. Diabetes Care. 2023.
8. Lau DCW et al. Pharmacokinetic comparison of compounded and brand-name semaglutide formulations. Journal of Pharmaceutical Sciences. 2025.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS program pooled analysis. Diabetes Obesity and Metabolism. 2023.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: STEP 4 trial. JAMA. 2021.
12. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. FDA Drug Shortage Database. Semaglutide and Tirzepatide shortage status. Updated April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.